

## Patisiran: Observation Period After Infusion

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for ONPATTRO<sup>®</sup> (patisiran) is provided [here](#). Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at [RNAiScience.com](http://RNAiScience.com).

### SUMMARY

- In the APOLLO, APOLLO-B, Global OLE, and HELIOS-A studies, patients were observed for 1 hour following completion of the patisiran infusion.<sup>1-4</sup>

### INDEX

[Label Information](#) – [Clinical Data](#) – [Abbreviations](#) – [References](#)

### ONPATTRO PRESCRIBING INFORMATION – RELEVANT CONTENT

The DOSAGE AND ADMINISTRATION section provides the following information<sup>5</sup>:

*Observe the patient during the infusion and, if clinically indicated, following the infusion.*

### CLINICAL DATA

#### APOLLO Study

APOLLO was a multicenter, international, randomized (2:1), double-blind, placebo-controlled, phase 3 study designed to assess the efficacy and safety of IV patisiran 0.3 mg/kg every 3 weeks (n=148) versus placebo (n=77) in patients with the polyneuropathy of hATTR. The primary endpoint was the change from baseline in the mNIS+7 at 18 months.<sup>6</sup>

#### APOLLO-B Study

APOLLO-B was a multicenter, randomized (1:1), double-blind, placebo-controlled, phase 3 study designed to evaluate the efficacy and safety of IV patisiran 0.3 mg/kg every 3 weeks (n=181) versus placebo (n=179) in patients with ATTR amyloidosis with cardiomyopathy, including both hATTR and wtATTR. The primary endpoint was the change from baseline in the 6-MWT at 12 months. After the 12-month double-blind treatment period, all patients received patisiran in an open-label extension period.<sup>7</sup>

#### Global Open-Label Extension Study

The Global OLE study (N=211) was a multicenter, international study designed to evaluate the long-term safety and efficacy of IV patisiran in patients with the polyneuropathy of hATTR. Patients with the polyneuropathy of hATTR who completed the patisiran Phase 2 OLE study or phase 3 APOLLO study and met eligibility criteria were able to start or continue IV patisiran 0.3 mg/kg every 3 weeks for up to 5 years. The study enrolled 25 patients from the patisiran Phase 2 OLE study (Phase 2 OLE-patisiran group), 137 patients from the APOLLO-patisiran arm (APOLLO-patisiran group), and 49 patients from the APOLLO-placebo arm (APOLLO-placebo group).<sup>8</sup>

## HELIOS-A Study

HELIOS-A was a phase 3, global, randomized, open-label study designed to evaluate the efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR. Patients were randomized (3:1) to receive either vutrisiran 25 mg every 3 months by subcutaneous injection (n=122) or patisiran 0.3 mg/kg every 3 weeks by IV infusion (as a reference group, n=42) for 18 months. This study used the placebo arm of the APOLLO study (NCT01960348) as an external control arm (n=77) for the primary endpoint and most other efficacy endpoints. The primary endpoint was the change from baseline in mNIS+7 at 9 months.<sup>9</sup>

## Observation Period After Infusion

In the APOLLO, APOLLO-B, Global OLE, and HELIOS-A studies, the patient's infusion site was assessed for signs of any localized reaction during the infusion and for 30 minutes after the end of the patisiran infusion. The patient was observed for 1 hour following completion of the patisiran infusion.<sup>1-4</sup>

## ABBREVIATIONS

6-MWT = 6-minute walk test; hATTR = hereditary transthyretin amyloidosis; wtATTR = wild-type transthyretin amyloidosis; IV = intravenous; mNIS+7 = modified Neuropathy Impairment Score +7; OLE = open-label extension.

Updated 20 August 2024

## REFERENCES

1. Protocol for: Adams D, González-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):11-21. doi:10.1056/NEJMoa1716153
2. Protocol for: Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. *N Engl J Med.* 2023;389(17):1553-1565. doi:10.1056/NEJMoa2300757
3. Alnylam Pharmaceuticals. Data on file. MED-ALL-TTR02-1800584.
4. Alnylam Pharmaceuticals. Data on file. MED-ALL-TTRSC02-2300015.
5. ONPATTRO (patisiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
6. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):11-21. doi:10.1056/NEJMoa1716153
7. Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. *N Engl J Med.* 2023;389(17):1553-1565. doi:10.1056/NEJMoa2300757
8. Adams, Polydefkis, González-Duarte, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. *Lancet Neurol.* 2021;20(1):49-59. doi:10.1016/S1474-4422(20)30368-9
9. Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. *Amyloid.* 2023;30(1):18-26. doi:10.1080/13506129.2022.2091985